Lizoforce Dry Syrup contains Linezolid 100mg/5ml, an oxazolidinone-class antibiotic effective against a broad spectrum of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). It is indicated for the treatment of complicated skin and soft tissue infections, community-acquired pneumonia, and infections caused by susceptible strains of bacteria in pediatric patients. The dry syrup formulation is designed for oral suspension, facilitating accurate dosing and improved compliance in children who have difficulty swallowing tablets. Linezolid acts by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. Lizoforce Dry Syrup should be administered as prescribed, with dosage adjustments based on the severity of infection and patient weight. It is important to complete the full course of therapy to prevent resistance development. Common adverse effects may include gastrointestinal disturbances, headache, and reversible myelosuppression with prolonged use. Caution is advised in patients with a history of hematologic disorders or those receiving serotonergic agents due to the risk of serotonin syndrome. Regular monitoring of blood counts is recommended during extended therapy.